5-day moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis: a cost-minimization analysis Source: Eur Respir J 2003; 22: Suppl. 45, 336s Year: 2003
3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001
Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 566s Year: 2003
Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003
Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003
Correlation between eradication of infecting organism on days 3-5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Medium dose budesonide/formoterol in fixed combination improves lung function over 2-3 weeks in patients with acute obstructive bronchitis of viral etiology Source: Annual Congress 2010 - Airway responsiveness, chronic cough and bronchiectasis: a modern approach Year: 2010
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004) Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp ) in pts with acute exacerbation of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Source: Eur Respir J 2012; 40: 17-27 Year: 2012
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval Source: Eur Respir J 2004; 24: 947-953 Year: 2004
Clinical evaluation of patients with acute exacerbation of chronic bronchitis treated emperically with telithromycin Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004
The effect of 3 months oral clarithromycin on sputum bacterial colonization in stable moderate- to- severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2016 – Clinical update on bronchiectasis Year: 2016